Skip to main content

Table 5 Description weekly urticarial score, DLQI, Cu-Q2oL, presence of angioedema at baseline and change by intervention administered

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Study ID Sample size Intervention Weekly urticaria score at baseline Change in weekly urticaria score (mean ± SD) DLQI baseline (mean ± SD) Change in DLQI (mean ± SD) Cu-Q2oL improvement (%) Presence of angioedema baseline, n (%) Angioedema free days (%)
1 27 Omalizumab 75-375 mg - −9,2Ϯ - 62,4* 50 - 77,8
22 Placebo - −3,3 - 15,3* 6,3 - 36,4
2 23 Omalizumab 75 mg 14,2 ± 5,71 −5,3 ± 6,91 - - - - -
25 Omalizumab 300 mg 14,7 ± 4,62 −10,7 ± 6,75Ϯ - - - - -
21 Omalizumab 600 mg 14,2 ± 4,81 −8,1 ± 6,0 - - - - -
21 Placebo 17 ± 4,79 −3,5 ± 5,17 - - - - -
3 82 75 mg omalizumab 16,8 ± 4,2 −7,2 ± 7,0 12,6 ± 6,5 −7,5 ± 7,2 - 31 (38) 93,5
83 150 mg omalizumab 17,1 ± 4,1 −9,8 ± 7,3Ϯ 13 ± 6,1 −8,3 ± 6,3 - 38 (46) 91,6
79 300 mg omalizumab 15,8 ± 4,6 −12,0 ± 7,6Ϯ 12,7 ± 6,4 −10,2 ± 6,8Ϯ - 32 (41) 95,5
79 placebo 17 ± 4,2 −5,2 ± 6,6 12,6 ± 5,9 −6,1 ± 7,5 - 30 (38) 89,2Ϯ
4 252 Omalizumab 300 mg 17,1 ± 4,2 −10,5 (−11,4 a −9,5) - −9,7 (−10,6 a −8,8) −3,9 (−4,9 a −3,0) 137 (54,4) 91Ϯ
94 Placebo 16,4 ± 4,6 −4,5 (−5,9 a −3,1)* - −5,1 (−7,0 a −3,2)* −2,7 (−3,8 a −1,6)* 41 (49,4) 88,1
5 78 Omalizumab 75 mg 17,2 ± 4,2   12,8 ± 6,1    35 (45,5)  
80 Omalizumab 150 mg 16,2 ± 4,6   13,6 ± 7,1    38 (47,5)  
81 Omalizumab 300 mg 17,1 ± 3,8   13,0 ± 6,7 10,29 (7,3)   34 (42,0) 96,1
80 Placebo 16,7 ± 4,4   14,0 ± 6,6 6,13 (5,25)   44 (55,0) 88,2
  1. SD: standard deviation, DLQI: Dermatologic Life Quality Intex, Cu-Q2oL: Chronic urticaria Quality of Life Questionnaire, *mean and 95% confidence interval, Ϯ p < 0.01 compared to placebo.